다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Gynecologic oncology, v.129 no.2, 2013년, pp.377 - 383
Kaijser, J. , Van Gorp, T. , Van Hoorde, K. , Van Holsbeke, C. , Sayasneh, A. , Vergote, I. , Bourne, T. , Timmerman, D. , Van Calster, B.
AI-Helper
Objective: The identification of novel biomarkers led to the development of the ROMA algorithm incorporating both HE4 and CA125 to predict malignancy in women with a pelvic mass. An ultrasound based prediction model (LR2) developed by the International Ovarian Tumor Analysis (IOTA) study offers bett...
Lancet Oncol Bouchard 7 167 2006 10.1016/S1470-2045(06)70579-4 Proteins with whey-acidic-protein motifs and cancer
Mod Pathol Galgano 19 847 2006 10.1038/modpathol.3800612 Comprehensive analysis of HE4 expression in normal and malignant human tissue
Oncogene Bingle 21 2768 2002 10.1038/sj.onc.1205363 The putative ovarian tumour marker gene HE4 (WFCD2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms
Cancer Res Drapkin 65 2162 2005 10.1158/0008-5472.CAN-04-3924 Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
Gynecol Oncol Moore 108 402 2008 10.1016/j.ygyno.2007.10.017 The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
Cancer Res Hellstrom 63 3695 2003 The HE4 (WFCD2) protein is a biomarker for ovarian carcinoma
Am J Obstet Gynecol Moore 206 4 351.e1 2012 10.1016/j.ajog.2011.12.029 Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders
Gynecol Oncol Nolen 117 440 2010 10.1016/j.ygyno.2010.02.005 Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass
Gynecol Oncol Moore 112 40 2009 10.1016/j.ygyno.2008.08.031 A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Obstet Gynecol Moore 118 2 part 1 280 2011 10.1097/AOG.0b013e318224fce2 Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass
Cancer Epidemiol Biomarkers Prev Bandiera 20 2496 2011 10.1158/1055-9965.EPI-11-0635 Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management
Clin Chem Lab Med Kim 49 527 2011 10.1515/CCLM.2011.085 Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population
Clin Chem Lab Med Lenhard 49 12 2081 2011 10.1515/CCLM.2011.709 The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses
Tumor Biol. Molina 32 1087 2011 10.1007/s13277-011-0204-3 HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases
Clin Chim Acta Ruggeri 412 1447 2011 10.1016/j.cca.2011.04.028 HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm
Br J Cancer Van Gorp 104 5 863 2011 10.1038/sj.bjc.6606092 HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
Clin Chem Lab Med Montagnana 49 3 521 2011 10.1515/CCLM.2011.075 The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Gynecol Oncol Jacob 121 487 2011 10.1016/j.ygyno.2011.02.022 No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
J Clin Oncol Timmerman 25 4194 2007 10.1200/JCO.2006.09.5943 Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors
J Natl Cancer Inst Van Calster 99 1706 2007 10.1093/jnci/djm199 Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125
Ultrasound Obstet Gynecol Valentin 34 345 2009 10.1002/uog.6415 Adding a single CA-125 measurement to ultrasound performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses
Clin Cancer Res Van Holsbeke 18 3 815 2012 10.1158/1078-0432.CCR-11-0879 External validation of diagnostic models to estimate the risk of malignancy in adnexal masses
Ultrasound Obstet Gynecol Nunes 2012 10.1002/uog.11088 A prospective evaluation of the IOTA Logistic Regression Model (LR2) for the diagnosis of ovarian cancer [published online ahead of print January 5, 2012]
Ultrasound Obstet Gynecol Timmerman 16 500 2000 10.1046/j.1469-0705.2000.00287.x Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group
2003 World Health Organization classification of tumours. Pathology and genetics of the breast and female genital organs
Biometrics DeLong 44 837 1988 10.2307/2531595 Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
Stat Med Pencina 27 157 2008 10.1002/sim.2929 Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond
Int J Gynecol Cancer Paulsen 16 Suppl. 1 11 2006 10.1111/j.1525-1438.2006.00319.x Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Clin Cancer Res Van Holsbeke 15 684 2009 10.1158/1078-0432.CCR-08-0113 Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study
Ultrasound Obstet Gynecol Timmerman 36 2 226 2010 10.1002/uog.7636 Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group
Am J Obstet Gynecol Moore 203 228e1 2010 10.1016/j.ajog.2010.03.043 Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
J Natl Cancer Inst Trimbos 95 2 113 2003 10.1093/jnci/95.2.113
JAMA Lijmer 11 1061 1999 10.1001/jama.282.11.1061 Empirical evidence of design-related bias in studies of diagnostic tests
Ultrasound Obstet Gynecol Ameye 40 5 582 2012 10.1002/uog.11177 Clinically oriented three-step strategy for assessment of adnexal pathology
Eur J Cancer Van Gorp 48 11 1649 2012 10.1016/j.ejca.2011.12.003 Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses
Ultrasound Obstet Gynecol Timmerman 13 1 11 1999 10.1046/j.1469-0705.1999.13010011.x Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience
Ultrasound Obstet Gynecol Valentin 18 4 357 2001 10.1046/j.0960-7692.2001.00500.x Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.